TLIS Stock Recent News

Talis Biomedical (NASDAQ: TLIS ) stock is falling on Wednesday after the company provided investors with an update on its restructuring plans. Talis Biomedical has brought on two new board members in Patricia Ferrari and John Young, Jr. These two have also elected to serve on a special committee focused on the restructuring of the company.

REDWOOD CITY, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that it will report second quarter 2023 financial results and provide a business update on Thursday, August 10, 2023, after market close. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).

Talis Biomedical Corporation (NASDAQ:TLIS ) Q1 2023 Earnings Conference Call May 11, 2023 6:00 PM ET Company Participants Emily Faucette - Senior Vice President, Corporate Communications & Investor Relations Rob Kelley - Chief Executive Officer Becky Markovich - Interim Chief Financial Officer Conference Call Participants Mark Massaro - BTIG Operator Good day and thank you for standing by. Welcome to the Talis Biomedical's Business Update Conference Call.

REDWOOD CITY, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that it will provide a business update and financial results on Thursday, May 11, 2023, after market close. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).

Talis Biomedical Corporation (NASDAQ:TLIS ) Q2 2022 Earnings Conference Call August 1, 2022 4:30 PM ET Company Participants Emily Faucette - Senior Vice President, Corporate Communications & Investor Relations Rob Kelley - Chief Executive Officer Roger Moody - Chief Financial Officer Conference Call Participants Casey Woodring - JPMorgan Mike Ryskin - Bank of America Mark Massaro - BTIG Operator Good day and thank you for standing by. Welcome to the Talis Biomedical's Business Update Conference Call.

Talis Biomedical Corporation (NASDAQ:TLIS ) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Emily Faucette - SVP-Corporate Communications and IR Rob Kelley - CEO Roger Moody - CFO Conference Call Participants Rachel Vatnsdal - JPMorgan Derik De Bruin - Bank of America Mark Massaro - BTIG Operator Thank you all for standing by, and welcome to Talis's First Quarter 2022 Earnings Conference Call. [Operator Instructions] I'll now turn the call over to your host, Emily Faucette.

MENLO PARK, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation ("TLIS"), a company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that it will report first quarter financial results on Tuesday, May 10, 2022, after market close. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).

Shares of Talis Biomedical Corp. TLIS, +2.34% bounced 1.9% in midday trading Monday, after the diagnostic testing company requested a withdrawal of a large share offering by a selling shareholder. After the March 15 closing bell, the company had registered 37.49 million common shares for sale, including 7.63 million common shares and 29.86 million shares issuable after the conversion of convertible preferred stock, by entities affiliated with Baker Bros.